Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 73 results.
User Information
Export Records
  1. 1.   Recreational Physical Activity, Sitting, and Androgen Metabolism among Postmenopausal Women in the Women's Health Initiative Observational Study
  2. Oh, Hannah; Saquib, Nazmus; Ochs-Balcom, Heather M.; Pfeiffer, Ruth M.; Richey, Phyllis A.; Shadyab, Aladdin H.; Wild, Robert A.; Underland, Lisa; Anderson, Garnet L.; Xu,Xia; Trabert, Britton
  3. Cancer Epidemiology Biomarkers & Prevention. 2022, Jan; 31(1): 97-107.
  1. 2.   A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma
  2. Ramaswami, Ramya; Uldrick, Thomas S; Polizzotto, Mark N; Wyvill, Kathleen M; Goncalves, Priscila; Widell, Anaida; Lurain, Kathryn; Steinberg, Seth M; Figg, William D; Tosato, Giovanna; Whitby,Denise; Yarchoan, Robert
  3. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019, JUL 15; 25(14): 4238-4247.
  1. 3.   Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors
  2. Weiss, Jonathan; Davies, Luke C.; Karwan, Megan; Ileva, Lilia; Ozaki, Michelle K.; Cheng, Robert; Ridnour, Lisa; Annunziata, Christina M.; Wink, David; McVicar, Daniel
  3. Journal of Clinical Investigation. 2018, Aug 31; 128(9): 3794-3805.
  1. 4.   Advances in using PARP inhibitors to treat cancer
  2. Kummar, S.; Chen, A.; Parchment, R. E.; Kinders, R. J.; Ji, J.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Bmc Medicine. 2012, Mar; 10
  1. 5.   Fine mapping of 14q24.1 breast cancer susceptibility locus
  2. Lee, P.; Fu, Y. P.; Figueroa, J. D.; Prokunina-Olsson, L.; Gonzalez-Bosquet, J.; Kraft, P.; Wang, Z. M.; Jacobs, K. B.; Yeager, M.; Horner, M. J.; Hankinson, S. E.; Hutchinson, A.; Chatterjee, N.; Garcia-Closas, M.; Ziegler, R. G.; Berg, C. D.; Buys, S. S.; McCarty, C. A.; Feigelson, H. S.; Thun, M. J.; Diver, R.; Prentice, R.; Jackson, R.; Kooperberg, C.; Chlebowski, R.; Lissowska, J.; Peplonska, B.; Brinton, L. A.; Tucker, M.; Fraumeni, J. F.; Hoover, R. N.; Thomas, G.; Hunter, D. J.; Chanock, S. J.
  3. Human Genetics. 2012, Mar; 131(3): 479-490.
  1. 6.   Rapid Cancer Detection by Topically Spraying a gamma-Glutamyltranspeptidase-Activated Fluorescent Probe
  2. Urano, Y.; Sakabe, M.; Kosaka, N.; Ogawa, M.; Mitsunaga, M.; Asanuma, D.; Kamiya, M.; Young, M. R.; Nagano, T.; Choyke, P. L.; Kobayashi, H.
  3. Science Translational Medicine. 2011, Nov; 3(110): 10.
  1. 7.   The B-Raf Status of Tumor Cells May Be a Significant Determinant of Both Antitumor and Anti-Angiogenic Effects of Pazopanib in Xenograft Tumor Models
  2. Gril, B.; Palmieri, D.; Qian, Y.; Anwar, T.; Ileva, L.; Bernardo, M.; Choyke, P.; Liewehr, D. J.; Steinberg, S. M.; Steeg, P. S.
  3. Plos One. 2011, Oct; 6(10): 11.
  1. 8.   Synthesis and Biological Activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyri midin-4-aminium Chloride as Potent Cytotoxic Antitubulin Agents
  2. Ganglee, A.; Zhao, Y.; Hamel, E.; Westbrook, C.; Mooberry, S. L.
  3. Journal of Medicinal Chemistry. 2011, Sep; 54(17): 6151-6155.
  1. 9.   Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding
  2. Zhang, Y. J.; Chertov, O.; Zhang, J. L.; Hassan, R.; Pastan, I.
  3. Cancer Research. 2011, Sep; 71(17): 5915-5922.
  1. 10.   A novel high-affinity human monoclonal antibody to mesothelin
  2. Ho, M.; Feng, M. Q.; Fisher, R. J.; Rader, C.; Pastan, I.
  3. International Journal of Cancer. 2011, May; 128(9): 2020-2030.
  1. 11.   A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity
  2. Feng, Y.; Shen, J. Y.; Streaker, E. D.; Lockwood, M.; Zhu, Z. Y.; Low, P. S.; Dimitrov, D. S.
  3. Arthritis Research & Therapy. 2011, Apr 8; 13(2): 12.
  1. 12.   A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases
  2. Kimball, K. J.; Preuss, M. A.; Barnes, M. N.; Wang, M. H.; Siegal, G. P.; Wan, W.; Kuo, H. C.; Saddekni, S.; Stockard, C. R.; Grizzle, W. E.; Harris, R. D.; Aurigemma, R.; Curiel, D. T.; Alvarez, R. D.
  3. Clinical Cancer Research. 2010, Nov; 16(21): 5277-5287.
  1. 13.   Oncogene-Driven Intrinsic Inflammation Induces Leukocyte Production of Tumor Necrosis Factor That Critically Contributes to Mammary Carcinogenesis
  2. Sangaletti, S.; Tripodo, C.; Ratti, C.; Piconese, S.; Porcasi, R.; Salcedo, R.; Trinchieri, G.; Colombo, M. P.; Chiodoni, C.
  3. Cancer Research. 2010, Oct; 70(20): 7764-7775.
  1. 14.   Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax
  2. Garg, H.; Salcedo, R.; Trinchieri, G.; Blumenthal, R.
  3. Cancer Gene Therapy. 2010, Mar; 17(3): 155-163.
  1. 15.   A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity
  2. Feng, Y.; Xiao, X. D.; Zhu, Z. Y.; Streaker, E.; Ho, M.; Pastan, I.; Dimitrov, D. S.
  3. Molecular Cancer Therapeutics. 2009, May; 8(5): 1113-1118.
  1. 16.   Electrophoresis and liquid chromatography/tandem mass spectrometry in disease biomarker discovery
  2. Issaq, H. J.; Blonder, J.
  3. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences. 2009 877(13): 1222-1228.
  1. 17.   Truncation of Histone H2A's C-terminal Tail, as Is Typical for Ni(II)-Assisted Specific Peptide Bond Hydrolysis, Has Gene Expression Altering Effects
  2. Karaczyn, A. A.; Cheng, R.; Buzard, G. S.; Hartley, J.; Esposito, D.; Kasprzak, K. S.
  3. Annals of Clinical and Laboratory Science. 2009 39(3): 251-262.
  1. 18.   Loss of Rad51c Leads to Embryonic Lethality and Modulation of Trp53-Dependent Tumorigenesis in Mice
  2. Kuznetsov, S. G.; Haines, D. C.; Martin, B. K.; Sharan, S. K.
  3. Cancer Research. 2009 69(3): 863-872.
  1. 19.   DNA fingerprinting of the NCI-60 cell line panel
  2. Lorenzi, P. L.; Reinhold, W. C.; Varma, S.; Hutchinson, A. A.; Pommier, Y.; Chanock, S. J.; Weinstein, J. N.
  3. Molecular Cancer Therapeutics. 2009 8(4): 713-724.
  1. 20.   Clinical Use of Interferon-gamma
  2. Miller, C. H. T.; Maher, S. G.; Young, H. A.; Donnelly, R. P.
  3. Cytokine Therapies: Novel Approaches for Clinical Indications. 2009; 1182 : 69-79.
  1. 21.   A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors
  2. Azad, N.; Perroy, A.; Gardner, E.; Imamura, C. K.; Graves, C.; Sarosy, G. A.; Minasian, L.; Kotz, H.; Raggio, M.; Figg, W. D.; Kohn, E. C.
  3. Cancer Biology & Therapy. 2009 8(19): 1800-1805.
  1. 22.   Experimental validation for quantitative protein network models
  2. Nishizuka, S.; Spurrier, B.
  3. Current Opinion in Biotechnology. 2008 19(1): 41-49.
  1. 23.   Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide
  2. Myers, R. M.; Greiner, S. M.; Harvey, M. E.; Griesmann, G.; Jkuffel, M.; Buhrow, S. A.; Reid, J. M.; Federspiel, M.; Ames, M. M.; Dingli, D.; Schweikart, K.; Welch, A.; Dispenzieri, A.; Peng, K. W.; Russell, S. J.
  3. Clinical Pharmacology & Therapeutics. 2007, Dec; 82(6): 700-710.
  1. 24.   Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1
  2. Li, P.; Jiang, S.; Lee, S. L.; Lin, C. Y.; Johnson, M. D.; Dickson, R. B.; Michejda, C. J.; Roller, P. P.
  3. Journal of Medicinal Chemistry. 2007, Nov; 50(24): 5976-5983.
  1. 25.   Proteomic analysis of protein expression changes in a model of gliomagenesis
  2. McBee, J. K.; Yu, L. R.; Kinoshita, Y.; Uo, T.; Beyer, R. P.; Veenstra, T. D.; Morrison, R. S.
  3. Proteomics Clinical Applications. 2007, Nov; 1(11): 1485-1498.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel